Medicare Beneficiaries Hoping GLP-1 Coverage for Weight Loss
A policy push to cover GLP-1 drugs for weight loss under Medicare stalled, leaving many beneficiaries in the middle. ...
GLP-1
This tag page compiles 4 articles on GLP-1 trends, pricing, and weight-loss stock impacts, helping you understand how drug costs and market moves affect personal finances.
41 articlesCanada India Have Generic Wegovy? Why the U.S. Keeps Lagging
Investors are weighing a potential pricing shift if canada india have generic Wegovy becomes reality, even as the U.S...
Could Viking Therapeutics Next: Will It Challenge Lilly?
The race to own the GLP-1 weight loss market has a new challenger in Viking Therapeutics. This article breaks down wh...
Best Weight Loss Drug Stocks to Buy in 2026: Top Picks
As GLP-1 therapies reshape obesity treatment, investors eye the best weight loss drug stock bets for 2026. This guide...
Three Biotechs That Takeover: Top 2026 M&A Targets
As large pharma hunts for GLP-1 and cardiovascular assets, three biotechs stand out as hot takeover targets. This rep...
Should Lilly Investors Worry About Its Rival From Within
Eli Lilly dominates the GLP-1 space, but competition is heating up from outside and inside its own lineup. This guide...
Is Novo Nordisk's Rebound Real--Or Head Fake for Investors?
After a steep slide, Novo Nordisk has shown fresh momentum. But can the rebound sustain, or is it just a temporary bo...
Will Medicare Cover Ozempic? What Retirees Should Know About GLP-1 Coverage
GLP-1 drugs like Ozempic and Wegovy are changing the cost landscape for retirees. This guide breaks down what Medicar...
Forget Oral Wegovy: This Could Be a Bigger Win for Investors
The launch of oral Wegovy marked a turning point for weight-loss drugs and stock investors. But a newer, rival oral G...
Lilly Falls on Oral Obesity Pill as FDA Decision Looms
Eli Lilly stock fell about 5% as investors awaited the FDA's April decision on orforglipron. Novo Nordisk's intensifi...
Is There Much Bullishness Priced Into Eli Lilly Stock?
Eli Lilly has enjoyed rapid growth from GLP-1 drugs, but sky-high expectations invite questions about valuations. Thi...
Lilly Just Opened Door to a GLP-1 Growth Boom in Markets
Eli Lilly unveiled a direct-to-employer program for Zepbound, aiming to accelerate GLP-1 adoption and expand market s...